Five things for pharma marketers to know: Wednesday, March 21, 2018

Share this content:

Johnson & Johnson CFO Dominic Caruso is planning to retire in September. “Dominic made a big impact inside our company, and he is well-respected throughout our industry,” said CEO Alex Gorsky. He will be replaced by Joseph Wolk, VP of investor relations, who has worked at J&J for 19 years. (Wall Street Journal)

GlaxoSmithKline head of pharmaceuticals Luke Miels is turning the business' focus toward areas like oncology and immunology. “In R&D, we're trying to pick which assets are most productive and are going to add the most value to patients. Well, we need to do the same thing in the commercial organization,” said Miels. An antibody drug for multiple myeloma and new kinds of immunotherapy and cell therapies could be launched by 2020. (Reuters)

The House did not include Obamacare payments that would lower health insurance premiums in the government funding bill. This was largely due to the dispute between Republicans and Democrats over abortion restrictions, known as the Hyde Amendment. Sens. Susan Collins (R-ME) and Lamar Alexander (R-TN) had backed the effort. (The Hill)

The House Energy and Commerce Committee questioned DEA director Robert Patterson on Tuesday about the opioid crisis. “Your agency doesn't appear to be willing to aggressively try to help us solve, or at least deal with, this crisis,” said Rep. Joe Barton (R-TX). The drug-reporting database, ARCOS, can be used to analyze how many painkillers are distributed to specific pharmacies. Patterson said this data has not been used but could be key to addressing the opioid crisis. (Washington Post)

MM&M has named its healthcare transformers and innovation catalysts for 2018. This annual showcase celebrates executives, investors, entrepreneurs, designers, and thinkers who are dedicated to helping the industry go “beyond the pill.” (MM&M)

Share this content:
Scroll down to see the next article